[The newer antipsychotic cariprazine (reagila): perspectives for use in different stages of schizophrenia therapy].
S V IvanovE I VoronovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2021)
Cariprazine is a newer 3rd generation antipsychotic acting as partial agonist for dopamine receptors with unique higher affinity for D3 than D2 receptors. This review article summarizes key data from preclinical and clinical studies of cariprazine including pharmacodynamics, pharmacokinetics, clinical efficacy and safety/acceptability in acute short-term and long-term maintenance and relapse prevention therapy in patients with schizophrenia. Efficacy and safety of cariprazine in patients schizophrenia with predominantly negative symptoms resistant to previous antipsychotic therapy is discussed as well.
Keyphrases
- bipolar disorder
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cells
- liver failure
- cell therapy
- prognostic factors
- intensive care unit
- drug induced
- machine learning
- hepatitis b virus
- patient reported outcomes
- mesenchymal stem cells
- uric acid
- replacement therapy
- bone marrow
- acute respiratory distress syndrome
- sleep quality
- extracorporeal membrane oxygenation
- aortic dissection